Medications remain the foundation of Parkinson’s treatment and are highly effective for many people, especially early in the disease. Over time, however, symptoms may become harder to control with medication alone. Fluctuations, wearing-off periods, or medication-related side effects can limit how well drug therapy continues to meet daily needs.

When medication alone is no longer providing consistent control, these advanced therapies can offer another layer of support, helping smooth fluctuations, reduce specific symptoms, and improve day-to-day function. Moving beyond medication is not a one-size-fits-all decision. It’s a thoughtful conversation between you and your movement disorder specialist, guided by your symptoms, priorities, and goals.

Advanced and Emerging Parkinson’s Treatments

Parkinson’s Treatments

Parkinson’s care is rarely one-dimensional. It grows with experience and time. Each step builds a path forward.

Advanced treatment decisions take time and careful evaluation. They tend to evolve gradually. Each layer strengthens the overall plan.

Meds remain the foundation.
Sometimes another layer is needed.
That’s where advanced therapy comes in.

Progress takes observation and review. As patterns emerge, regular check-ins help keep your care aligned with your needs.

Exploring The Next Layer of Support in Parkinson’s Care

When Medication Isn’t Enough

For many people, medications provide strong, meaningful relief, especially early in Parkinson’s.

But Parkinson’s is progressive. Over time, even well-managed medication plans can become less predictable. Doses may wear off sooner. Symptoms may fluctuate. You might notice “on” and “off” periods that don’t feel as smooth or consistent as they once did.

This does not mean you’ve failed treatment, and it does not mean you’ve run out of options.

When medication alone is no longer providing steady control, additional therapies can offer another layer of support.

Some treatments deliver medication more continuously through pump systems.
Some use precisely targeted procedures in the brain, such as Deep Brain Stimulation (DBS) or Focused Ultrasound, to help regulate movement circuits more consistently.

These approaches are not first-line treatments. They are considered thoughtfully, in partnership with a movement disorder specialist, based on symptom patterns, daily function, age, cognition, and personal goals.

The goal is not perfection.
The goal is steadier days, fewer fluctuations, and improved quality of life.

Text

Call

Burger

Taco

Netflix

Hulu

Coffee

Tea

Winter

Summer

Dog

Cat

We have been a speaker at 3 events before we decided to start our podcast!

three.

We've traveled to all the continents and the north still holds our hearts.

two.

Our pup Murphy is liiiiiife! He may even make an appearance on the pod!

one.

Fun Details

What Parkinson’s Medications Actually Target

Disease-targeting treatments focus on replacing dopamine, mimicking its effects, or helping existing dopamine last longer in the brain. These medications form the foundation of Parkinson’s treatment and are most effective for movement-related symptoms such as slowness, stiffness, and tremor.

Symptom-targeted treatments are used to address specific challenges that may not respond fully to dopamine-based therapy alone. These can include motor symptoms (such as dyskinesia or tremor) as well as non-motor symptoms (such as sleep problems, mood changes, or autonomic issues). While these treatments don’t directly change dopamine levels, they can significantly improve day-to-day functioning and comfort.

Most people with Parkinson’s use a combination of both approaches, and treatment plans often evolve over time. Medications are adjusted based on symptoms, response, side effects, and stage of disease, with the shared goal of maintaining the best possible quality of life.
Status: Fully established, FDA-approved
What it is.
It is a surgical treatment option for some people with Parkinson’s Disease, typically considered when medication fluctuations become difficult to control.

DBS involves implanting electrodes in specific areas of the brain and connecting them to a device that delivers mild electrical stimulation. This stimulation helps regulate abnormal brain signals associated with Parkinson’s symptoms.

DBS offers several advantages:
  • It is adjustable and reversible
  • It can reduce motor fluctuations and medication side effects
  • It is especially helpful for tremor that does not respond well to medication

Earlier surgical approaches intentionally damaged brain tissue: DBS achieves similar benefits without permanent damage.


Deep Brain Stimulation (DBS) 

Status: Fully established, FDA-approved
What it does:

Delivers Levodopa continuously via a small pump connected to a tube placed directly into the small intestine. By bypassing the stomach, the medication is absorbed more predictably, avoiding delays caused by gastric emptying problems, protein interference, or inconsistent digestion. The result is a steadier level of Levodopa reaching the brain throughout the day.

Best for:

  • People with significant “on–off” fluctuations

  • Patients who benefit from Levodopa, but can’t maintain consistency


Key point: Often described as “Levodopa by IV-like drip, but for the gut”. This approach doesn’t change what medication is used, but how it’s delivered, turning an intermittent pill-based strategy into a more continuous, steady treatment.

Levodopa–Carbidopa Intestinal Gel (LCIG / Duopa)

Status: Widely used internationally; accepted advanced therapy

What it does:
Continuous delivery of a Dopamine Agonist via a small portable pump connected to a tiny needle placed under the skin. By delivering medication continuously rather than in intermittent doses, this therapy helps stabilize Dopamine stimulation in the brain and reduce sudden drops in motor control.

Why that matters:
As Parkinson’s progresses, the brain becomes more sensitive to fluctuating Dopamine levels. Continuous infusion delivers medication more steadily, helping prevent sudden ups and downs and keeping movement more consistent throughout the day.

Best for:

  • People experiencing frequent or severe OFF episodes

  • Patients not suitable for DBS

Key Point: Less common in the U.S., but standard in Europe and other regions

Continuous Apomorphine Infusion

Status: FDA-approved for specific indications
What it does:

Uses precisely targeted, high-intensity sound waves, guided by real-time MRI, to create a small, controlled lesion in a specific brain region involved in tremor. The procedure is performed without incisions, implants, or implanted hardware, and patients are typically awake so effects can be assessed immediately.

Why that matters:
Because there is no surgery or implanted device, focused ultrasound can be an option for people who want or need a non-implant, non-surgical approach to symptom control.

Best for:

  • Medication-resistant tremor, particularly when tremor is the dominant and most disabling symptom

  • Patients who are not candidates for DBS due to medical risk, cognitive concerns, or personal preference

Important limitations:

Treatment is typically one-sided only (to reduce risk of speech or balance problems)

The effect is not reversible or adjustable after the lesion is created

Benefits are strongest for tremor and less effective for other Parkinson’s symptoms such as stiffness or slowness

Focused Ultrasound Thalamotomy

What Parkinson’s Medications Actually Target

Disease-targeting treatments focus on replacing dopamine, mimicking its effects, or helping existing dopamine last longer in the brain. These medications form the foundation of Parkinson’s treatment and are most effective for movement-related symptoms such as slowness, stiffness, and tremor.

Symptom-targeted treatments are used to address specific challenges that may not respond fully to dopamine-based therapy alone. These can include motor symptoms (such as dyskinesia or tremor) as well as non-motor symptoms (such as sleep problems, mood changes, or autonomic issues). While these treatments don’t directly change dopamine levels, they can significantly improve day-to-day functioning and comfort.

Most people with Parkinson’s use a combination of both approaches, and treatment plans often evolve over time. Medications are adjusted based on symptoms, response, side effects, and stage of disease, with the shared goal of maintaining the best possible quality of life.

Hope With Caution: Navigating Emerging Parkinson’s Treatments

Current research directions

Research into Parkinson’s  continues to advance, including studies of stem cell therapies, gene therapies, and potential disease-modifying treatments. Many of these approaches aim to go beyond symptom management and, in some cases, target the underlying disease process itself. At present, however, most remain experimental, under active investigation, and not yet widely available.

These emerging therapies represent important areas of ongoing research and future promise, but their safety, effectiveness, durability, and long-term impact are still being carefully evaluated. As a result, access is generally limited to regulated clinical trials, where treatments are studied under strict scientific and ethical oversight, with close monitoring of dosing, outcomes, side effects, and potential risks.

Healthcare providers typically recommend discussing any experimental treatment, particularly those offered outside standard medical systems or overseas , with a Neurologist or movement disorder specialist before pursuing them. Individuals should also be cautious of social media posts, online advertisements, or direct messages that appear after internet searches and promise rapid, guaranteed, or “breakthrough” results. These targeted messages are often financially motivated, designed to exploit vulnerability and urgency, and may promote treatments that lack scientific evidence, regulatory oversight, or appropriate medical follow-up. Many such offerings are unproven at best and exploitative at worst.

When appropriate, participation in well-designed clinical trials offers the safest and most responsible way to access emerging therapies while also contributing to research that helps advance Parkinson’s care for the broader community.

After Alzheimer’s disease, Parkinson’s is the second-most common neurodegenerative disorder in the U.S

Approximately 90,000 Americans are newly diagnosed with Parkinson’s every year, nearly double previous estimates.

1

2

3

4

5

6

7

8

9

10

Stem Cell–Based Therapies

Stem cell–based therapies aim to replace or support Dopamine-producing neurons that are lost in Parkinson’s by transplanting lab-grown cells into carefully targeted regions of the brain. The goal is for these cells to survive, integrate into existing neural circuits, and restore Dopamine signaling, potentially improving motor symptoms.

Current Phase Status:
  • Phase 1–3 Trials
  • Safety, cell survival, and early functional signals
  • Long-term durability still unknown

Key Point:
These are regulated academic/industry trials, not commercial stem-cell clinics.

next-gen Therapies/Treatment in development 

1 OF 10

1

Gene therapy for Parkinson’s 

Gene therapy for Parkinson’s uses modified, harmless viruses to deliver specific genes into targeted brain areas to improve Dopamine production, enhance how Levodopa works, or protect neurons from further damage.

Current phase status:
  • Phase 1–2
  • Focused on safety, dosing, and early signals of benefit
  • Early efficacy signals under evaluation

Key Point:
No gene therapy for Parkinson’s has reached Phase 3 yet

next-gen Therapies/Treatment in development 

2 OF 10

2

Alpha-Synuclein Targeted Therapies

Alpha-Synuclein–Targeted Therapies aim to reduce the buildup or spread of misfolded Alpha-Synuclein protein, which is believed to contribute to nerve cell damage in Parkinson’s. Most approaches use antibodies or vaccine-like strategies to help the immune system recognize and clear this protein;

Current Phase Status:
  • Several programs have completed Phase 2 trials, while others have been halted or reworked

Key Point:
To date, these therapies have shown acceptable safety but have not yet demonstrated a clear ability to slow disease progression.

next-gen Therapies/Treatment in development 

3 OF 10

3

Antisense Oligonucleotides (ASOs)

Antisense Oligonucleotides (ASOs) are short, lab-made pieces of genetic material. They’re designed to attach to a specific message inside a cell.

That “message” is called RNA (Ribonucleic Acid). RNA acts like a messenger, it carries instructions from your genes to the cell’s protein-making machinery.

When an ASO binds to a specific RNA message, it can reduce how much of a certain protein the body makes, especially proteins believed to play a role in Parkinson’s.

ASOs work by quieting down a genetic message before it turns into too much of the wrong protein.

In simple terms:
  • DNA is the instruction manual stored in the cell
  • RNA is the photocopy of one instruction
  • The cell uses that RNA copy to make a specific protein

Current Phase Status:
  • Phase 1
  • Safety, dosing, and target engagement


next-gen Therapies/Treatment in development 

4 OF 10

4

Neuron Protection & Repair (Neurotrophic Factors)

Neuron protection and repair strategies.  

GDNF (Glial Cell Line–Derived Neurotrophic Factor) is a natural growth protein that helps protect Dopamine-producing brain cells.  Unlike medications like Levodopa, which replace Dopamine, GDNF-based therapies aim to support the health and resilience of the neurons themselves.

Goal: Help existing neurons survive longer

Current phase status:

  • Phase 2 
  • Several approaches have reached Phase 2 clinical trials, but results have been mixed largely because safely and consistently delivering these factors to the right brain areas is difficult.

Key Point:
Biology makes sense; delivery remains the main hurdle.

next-gen Therapies/Treatment in development 

5 OF 10

5

Advanced Neuromodulation 

Advanced Neuromodulation builds on established therapies like Deep Brain Stimulation (DBS) by making brain stimulation more precise, adaptive, and personalized. This includes adaptive Deep Brain Stimulation (aDBS), an FDA-approved advancement that can adjust stimulation in real time based on brain activity.

Current Phase Status:
Both traditional DBS and adaptive systems are FDA-approved and widely used. Ongoing research now focuses on post-approval and optimization studies, refining how stimulation is delivered, improving programming strategies, and enhancing responsiveness. The goal is straightforward: better symptom control with fewer side effects.

Why It Matters:
For people living with Parkinson’s, this represents a meaningful evolution—not a brand-new therapy, but a smarter, more responsive version of an established one.

next-gen Therapies/Treatment in development 

6 OF 10

6

Focused Ultrasound (Advanced Use)

Research into Focused Ultrasound continues to expand the potential applications of this non-surgical, sound wave–based therapy beyond tremor, with studies now exploring its use for rigidity, Bradykinesia (slowness of movement), and medication-related motor fluctuations.

Current Phase Status:
  • It is FDA-approved for tremor-dominant Parkinson’s and is currently being studied in Phase 2–3 clinical trials for broader symptom control.

Key Point:
While it can significantly improve certain symptoms in carefully selected patients, it is symptom-focused and does not alter the underlying disease process.

next-gen Therapies/Treatment in development 

7 OF 10

7

Inflammation/ mitochondrial-targeted therapies 

Inflammation and Mitochondrial-targeted therapies focus on reducing chronic brain inflammation and improving how neurons produce and manage energy, two processes believed to contribute to ongoing nerve cell damage in Parkinson’s. These drugs aim to slow neuron stress and loss, potentially influencing disease progression rather than just symptoms.
Current Phase Status
  • At present, these approaches remain in clinical trials only, with studies primarily evaluating safety, biological effects, and early signals of benefit
  • All listed medications are investigational and not FDA-approved for Parkinson’s use.
  1. Phase 2: Ambroxol, UDCA
  2. Phase 1–2: Nilotinib
  3. Phase 1: NLRP3 inhibitors
  4. Phase 2–3 (negative): CoQ10, Creatine
Key Point
  • Several approaches show biological promise but results so far are mixed.
  • Participation in well-designed clinical trials is the safest way to access experimental therapies.

next-gen Therapies/Treatment in development 

8 OF 10

8

Gut–brain axis therapies

Gut–Brain Axis Therapies focus on the connection between the digestive system and the brain: particularly how gut bacteria and inflammation may influence Parkinson’s. These approaches aim to modify the Microbiome using targeted probiotics, diet-based interventions, or Microbiome-directed drugs to affect brain signaling and inflammation.

Current Phase Status:
  • Research in this area is very early, spanning preclinical studies through Phase 1 trials, with small human feasibility studies underway.
        
Key Point:
  •  While still experimental, it is a rapidly expanding field of Parkinson’s research.
  • Several gut-focused therapies used for other conditions are being studied in Parkinson’s, but none are approved or proven to modify the disease. 

next-gen Therapies/Treatment in development 

9 OF 10

9

Digital and wearable-guided therapies

Digital and Wearable-Guided Therapies use sensors, smartphone apps, and connected devices to continuously track movement, gait, tremor, sleep, and medication response in real-world settings. These tools are designed to improve symptom monitoring and treatment precision, helping clinicians fine-tune medication timing and better understand day-to-day fluctuations that are hard to capture during office visits.

Current Phase Status:
  • Several tools are already FDA-cleared and in clinical use, with ongoing validation studies underway; however, they are adjunctive technologies that support care rather than stand-alone treatments for Parkinson’s disease.

Key Point:
Adjunct tools — not stand-alone treatments.
helping clinicians adjust medication schedules and see how symptoms change throughout the day

next-gen Therapies/Treatment in development 

10 OF 10

10

What Parkinson’s Medications Actually Target

Disease-targeting treatments focus on replacing dopamine, mimicking its effects, or helping existing dopamine last longer in the brain. These medications form the foundation of Parkinson’s treatment and are most effective for movement-related symptoms such as slowness, stiffness, and tremor.

Symptom-targeted treatments are used to address specific challenges that may not respond fully to dopamine-based therapy alone. These can include motor symptoms (such as dyskinesia or tremor) as well as non-motor symptoms (such as sleep problems, mood changes, or autonomic issues). While these treatments don’t directly change dopamine levels, they can significantly improve day-to-day functioning and comfort.

Most people with Parkinson’s use a combination of both approaches, and treatment plans often evolve over time. Medications are adjusted based on symptoms, response, side effects, and stage of disease, with the shared goal of maintaining the best possible quality of life.

After Alzheimer’s disease, Parkinson’s is the second-most common neurodegenerative disorder in the U.S

Approximately 90,000 Americans are newly diagnosed with Parkinson’s every year, nearly double previous estimates.

mPower app: Research app (smartphone-based) that collects movement and symptom data for study purposes.

Speech and voice analysis apps:  Analyze voice changes as an adjunctive marker of symptom severity.

Medication tracking apps:  Reminders and logs that help correlate symptoms with medication timing.

Smartphone Apps & Digital Platforms

04

Emerging or Regionally Available Tools

STAT-ON™ 
Waist-worn sensor that tracks ON/OFF motor states and response to Levodopa (approved in parts of Europe; used in research/ specialty settings).

Wearable gait sensors  Various ankle/hip sensors tested in research to quantify stride length, balance, and freezing of gait.

03

Widely Used Consumer Devices 

Apple Watch
Tracks movement patterns, tremor indicators, and includes fall detection; not a PD diagnostic device, but useful for symptom tracking.

Fitbit and other activity trackers
Monitor activity levels and sleep patterns that can be correlated with medication response or fatigue.

02

Already FDA-Cleared /Clinically Used

PKG® (Personal KinetiGraph)  Wrist-worn sensor that tracks Bradykinesia, Dyskinesia, tremor, and motor state over days to help optimize medications

Kinesia™ ONE/Kinesia 360  Motion sensors that objectively measure tremor, Dyskinesia, and other motor features.

Mobility Lab/APDM sensors 
Wearable inertial sensors used in clinics to assess gait, balance, and fall risk.



01

Here are some examples of digital tools and wearables that are currently used (or studied) to help monitor and manage Parkinson’s symptoms:

Digital and wearable-guided therapies

Medications remain the foundation of Parkinson’s treatment and are highly effective for many people, especially early in the disease. Over time, however, symptoms may become harder to control with medication alone. Fluctuations, wearing-off periods, or medication-related side effects can limit how well therapy meets daily needs.

Deep Brain Stimulation (DBS) is one option, but pump-based therapies and focused ultrasound are also recognized treatments, depending on symptoms, age, cognition, lifestyle, and personal preference.

When medication alone is no longer providing consistent control, these advanced therapies can offer another layer of support, helping smooth fluctuations, reduce specific symptoms, and improve daily function. Moving beyond medication is not a one-size-fits-all decision. It’s a thoughtful conversation between you and your movement disorder specialist, guided by your symptoms, priorities, and goals. 
Clinical Trial Phases: At a Glance

Phase 1:  Safety
Small studies focused on safety, dosing, and side effects. Not designed to show effectiveness.
Phase 2:  Early Benefit
Medium-sized studies looking for early signs the treatment may help, while continuing to monitor safety.
Phase 3:  Confirmation
Large trials that confirm effectiveness, compare to standard care, and identify less common side effects.
FDA Approval
If a treatment successfully completes Phase 3:
  •      Data are reviewed by regulatory agencies 
  •      Treatment may be approved for general clinical use

Post-Approval (Phase 4)
Ongoing studies after approval to monitor real-world safety and refine how treatments are used.

Important note:
Some approved therapies (like DBS or digital tools) continue to evolve through post-approval studies.



Understanding Clinical Trials & What Each Phase Supports

The Phases of Research

Text

Call

Burger

Taco

Netflix

Hulu

Coffee

Tea

Winter

Summer

Dog

Cat

We have been a speaker at 3 events before we decided to start our podcast!

three.

We've traveled to all the continents and the north still holds our hearts.

two.

Our pup Murphy is liiiiiife! He may even make an appearance on the pod!

one.

Fun Details